Contineum Therapeutics, Inc. Class A Common Stock

NASDAQ:CTNM

Biotechnology

Healthcare
$9.24 -3.20%

-$0.39 today

Market cap
$326.66M
Beta
0.89
P/E (TTM)
-7.5
EPS (TTM)
-$1.57
52W Low $3.69High $16.33

Volume 0.20M

Average 0.26M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$55.31M

FY 2025 · Annual

Investing Cash Flow

-$3.71M

FY 2025 · Annual

Financing Cash Flow

$112.69M

FY 2025 · Annual

+3.4% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(29M)(24.25M)22.72M(42.26M)(59.98M)
Depreciation & Amortization325K329K195K258K323K
Deferred Income Tax00000
Stock-Based Compensation1.75M1.93M2.22M6.8M10.04M
Change in Working Capital108K(1.27M)(1.02M)5.33M(6.04M)
Accounts Receivables00000
Inventory00000
Accounts Payables(110K)(230K)01.14M(869K)
Other Working Capital218K(1.04M)(1.02M)4.19M(5.17M)
Other Non-Cash Items553K3.14M(4.76M)(2.98M)344K
Operating Cash Flow(26.27M)(20.12M)19.35M(32.85M)(55.31M)
Capital Expenditures(168K)(118K)(414K)(514K)(231K)
Acquisitions (Net)00020K0
Purchases of Investments(66.78M)(64.7M)(141.87M)(226.41M)(162.5M)
Sales of Investments1.98M87.12M76.71M157.16M159.02M
Other Investing Activities00000
Investing Cash Flow(64.97M)22.3M(65.57M)(69.74M)(3.71M)
Debt Repayment0(1.25M)(3.75M)00
Common Stock Issued000108.21M112.69M
Common Stock Repurchased0(4K)(28K)00
Dividends Paid00000
Other Financing Activities113K15K(184K)790K0
Financing Cash Flow79.84M(1.24M)56.18M109M112.69M
Effect of Forex Changes00000
Net Change in Cash(11.4M)939K9.96M6.42M53.66M
Free Cash Flow(26.43M)(20.24M)18.94M(33.36M)(55.54M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$60.0M
+ D&A$323.0K
+ Stock-Based Comp$10.0M
+ Deferred Tax$0
- Working Capital-$6.0M
+ Other Non-Cash$344.0K
= Operating Cash Flow-$55.3M
- Capex-$231.0K
= Free Cash Flow-$55.5M

Analysis

FY2025 free cash flow is -$55.5M. FCF conversion is 92.6% of net income. Operating cash flow was -$55.3M, with capex of -$231.0K. The largest bridge item is Stock-Based Comp at $10.0M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13G/ASC 13G/A filingNov 6, 2026
SC 13GSC 13G filingNov 5, 2026
10-QQuarterly reportNov 3, 2026
8-KCurrent reportNov 3, 2026
SC 13GSC 13G filingOct 28, 2026

Does CTNM generate free cash flow?

Contineum Therapeutics, Inc. Class A Common Stock (CTNM) generated -$55.54M of free cash flow in fiscal 2025.

How much operating cash flow does CTNM produce?

Operating cash flow was -$55.31M, before capital expenditures of $231,000.00.